Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Newer treatments for fibromyalgia syndrome

Authors Richard E Harris, Daniel J Clauw

Published 5 December 2008 Volume 2008:4(6) Pages 1331—1342

DOI http://dx.doi.org/10.2147/TCRM.S3396

Review by Single-blind

Peer reviewer comments 5

Richard E Harris, Daniel J Clauw

Department of Anesthesiology, The University of Michigan, Ann Arbor, MI, USA

Abstract: Fibromyalgia syndrome is a common chronic pain disorder of unknown etiology. The lack of understanding of the pathophysiology of fibromyalgia has made this condition frustrating for patients and clinicians alike. The most common symptoms of this disorder are chronic widespread pain, fatigue, sleep disturbances, difficulty with memory, and morning stiffness. Emerging evidence points towards augmented pain processing within the central nervous system (CNS) as having a primary role in the pathophysiology of this disorder. Currently the two drugs that are approved by the United States Food and Drug Administration (FDA) for the management of fibromyalgia are pregabalin and duloxetine. Newer data suggests that milnacipran, a dual norepinephrine and serotonin reuptake inhibitor, may be promising for the treatment of fibromyalgia. A double-blind, placebo-controlled trial of milnacipran in 125 fibromyalgia patients showed significant improvements relative to placebo. Milnacipran given either once or twice daily at doses up to 200 mg/day was generally well tolerated and yielded significant improvements relative to placebo on measures of pain, patient’s global impression of change in their disease state, physical function, and fatigue. Future studies are needed to validate the efficacy of milnacipran in fibromyalgia.

Keywords: fibromyalgia, pain, pharmacological, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Utility of proteomics in obstetric disorders: a review

Hernández-Núñez J, Valdés-Yong M

International Journal of Women's Health 2015, 7:385-391

Published Date: 13 April 2015

Porous microsphere and its applications

Cai Y, Chen Y, Hong X, Liu Z, Yuan W

International Journal of Nanomedicine 2013, 8:1111-1120

Published Date: 15 March 2013

Poly ε-caprolactone nanoparticles loaded with Uncaria tomentosa extract: preparation, characterization, and optimization using the Box–Behnken design

Ribero AF, de Oliveira Rezende RL, Cabral LM, de Sousa VP

International Journal of Nanomedicine 2013, 8:431-442

Published Date: 25 January 2013

Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache

Moore JC, Miner JR

Patient Preference and Adherence 2012, 6:27-37

Published Date: 4 January 2012

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors

Chang-Lin J-E, Batoosingh AL, Hollander DA, Schiffman RM, Tang-Liu D D-S.

Clinical Ophthalmology 2011, 5:1119-1120

Published Date: 10 August 2011

Dealing with grief related to loss by death and chronic pain: Suggestions for practice. Part 2

Elin Dysvik, Bodil Furnes

Patient Preference and Adherence 2010, 4:163-170

Published Date: 29 June 2010

Mirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects

Robert D Steigerwalt Jr, Gianni Belcaro, Paolo Morazzoni, et al

Clinical Ophthalmology 2010, 4:471-476

Published Date: 12 May 2010

Prevention of atherosclerosis in patients living with HIV

Ferruccio De Lorenzo, Marta Boffito, Sophie Collot-Teixeira, Brian Gazzard, John L McGregor, Kevin Shotliff, Han Xiao

Vascular Health and Risk Management 2009, 5:287-300

Published Date: 26 March 2009

Investigation of the association between the GLC3A locus and normal tension glaucoma in Japanese patients by microsatellite analysis

M Kamio, A Meguro, M Ota, N Nomura, K Kashiwagi, et al

Clinical Ophthalmology 2009, 3:183-188

Published Date: 13 January 2009

30-days mortality in patients with perforated peptic ulcer: A national audit

Anne Nakano, Jørgen Bendix, Sven Adamsen, Daniel Buck, Jan Mainz, et al

Risk Management and Healthcare Policy 2008, 1:31-38

Published Date: 30 November 2008